Hangzhou Tigermed Consulting Co., Ltd Stock
Equities
300347
CNE100001KV8
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49.19 CNY | -1.40% |
|
+0.63% | -9.94% |
| Capitalization | 40.33B 5.71B 4.86B 4.54B 4.26B 7.87B 515B 8.57B 52.88B 20.55B 243B 21.44B 20.99B 887B | P/E ratio 2025 * |
30.9x | P/E ratio 2026 * | 30.8x |
|---|---|---|---|---|---|
| Enterprise value | 39.44B 5.59B 4.75B 4.44B 4.16B 7.7B 504B 8.38B 51.72B 20.1B 238B 20.97B 20.53B 868B | EV / Sales 2025 * |
5.74x | EV / Sales 2026 * | 5.03x |
| Free-Float |
72.37% | Yield 2025 * |
1.04% | Yield 2026 * | 1% |
| 1 day | -1.40% | ||
| 1 week | +0.63% | ||
| Current month | -3.57% | ||
| 1 month | -16.37% | ||
| 3 months | -19.65% | ||
| 6 months | -6.41% | ||
| Current year | -9.94% |
| 1 week | 48.6 |  | 50.66 |
| 1 month | 47.9 | | 59.97 |
| Current year | 41.61 | | 71.9 |
| 1 year | 41.61 | | 71.9 |
| 3 years | 36.12 | | 130 |
| 5 years | 36.12 | | 209.41 |
| 10 years | 14.2 | | 209.41 |
| Manager | Title | Age | Since |
|---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 56 | - |
Cheng Cheng Yang
DFI | Director of Finance/CFO | 51 | 2022-10-20 |
Hao Wu
PSD | President | 58 | 2019-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Xiao Chun Cao
BRD | Director/Board Member | 56 | 2004-12-31 |
Xiao Ping Ye
CHM | Chairman | 62 | - |
Zhi Min Chen
BRD | Director/Board Member | 65 | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.40% | +0.63% | -24.64% | -46.24% | 5.78B | |
| -2.53% | -4.41% | +0.34% | +14.63% | 47.04B | |
| +1.37% | +0.47% | +12.39% | +8.37% | 37.96B | |
| -0.57% | -3.19% | +74.01% | +62.86% | 35.71B | |
| +0.54% | +2.25% | +10.68% | +17.47% | 27.64B | |
| +0.96% | +3.92% | +65.78% | +175.14% | 15.8B | |
| +0.81% | +0.04% | +69.09% | +230.15% | 15.06B | |
| +2.19% | +2.24% | -10.49% | -2.48% | 14.19B | |
| -1.61% | -3.24% | +71.01% | - | 13.36B | |
| +0.65% | -3.26% | +108.32% | +111.04% | 12.74B | |
| Average | +0.10% | -0.45% | +37.65% | +63.44% | 22.53B | |
| Weighted average by Cap. | -0.23% | -0.77% | +33.47% | +52.27% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 6.87B 974M 828M 773M 726M 1.34B 87.81B 1.46B 9.01B 3.5B 41.48B 3.65B 3.58B 151B | 7.82B 1.11B 943M 880M 826M 1.53B 99.98B 1.66B 10.26B 3.99B 47.23B 4.16B 4.07B 172B |
| Net income | 1.31B 186M 158M 147M 138M 256M 16.73B 278M 1.72B 667M 7.91B 696M 681M 28.8B | 1.46B 207M 176M 164M 154M 285M 18.66B 310M 1.91B 744M 8.82B 776M 760M 32.12B |
| Net Debt | -882M -125M -106M -99.24M -93.1M -172M -11.27B -187M -1.16B -449M -5.32B -469M -459M -19.4B | -990M -140M -119M -111M -105M -193M -12.65B -210M -1.3B -504M -5.98B -526M -515M -21.78B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-11 | 49.19 ¥ | -1.40% | 6,673,753 |
| 25-12-10 | 49.89 ¥ | +0.26% | 7,524,265 |
| 25-12-09 | 49.76 ¥ | +0.91% | 11,136,400 |
| 25-12-08 | 49.31 ¥ | -0.28% | 7,108,402 |
| 25-12-05 | 49.45 ¥ | +1.17% | 7,751,980 |
End-of-day quote Shenzhen S.E., December 10, 2025
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 300347 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition